Matches in SemOpenAlex for { <https://semopenalex.org/work/W3031325065> ?p ?o ?g. }
- W3031325065 endingPage "486" @default.
- W3031325065 startingPage "486" @default.
- W3031325065 abstract "The multidrug resistance-associated protein 2 (MRP2) mediates the biliary excretion of drugs and metabolites. [99mTc]mebrofenin may be employed as a probe for hepatic MRP2 activity because its biliary excretion is predominantly mediated by this transporter. As the liver uptake of [99mTc]mebrofenin depends on organic anion-transporting polypeptide (OATP) activity, a safe protocol for targeted inhibition of hepatic MRP2 is needed to study the intrinsic role of each transporter system. Diltiazem (DTZ) and cyclosporin A (CsA) were first confirmed to be potent MRP2 inhibitors in vitro. Dynamic acquisitions were performed in rats (n = 5–6 per group) to assess the kinetics of [99mTc]mebrofenin in the liver, intestine and heart-blood pool after increasing doses of inhibitors. Their impact on hepatic blood flow was assessed using Doppler ultrasound (n = 4). DTZ (s.c., 10 mg/kg) and low-dose CsA (i.v., 0.01 mg/kg) selectively decreased the transfer of [99mTc]mebrofenin from the liver to the bile (k3). Higher doses of DTZ and CsA did not further decrease k3 but dose-dependently decreased the uptake (k1) and backflux (k2) rate constants between blood and liver. High dose of DTZ (i.v., 3 mg/kg) but not CsA (i.v., 5 mg/kg) significantly decreased the blood flow in the portal vein and hepatic artery. Targeted pharmacological inhibition of hepatic MRP2 activity can be achieved in vivo without impacting OATP activity and liver blood flow. Clinical studies are warranted to validate [99mTc]mebrofenin in combination with low-dose CsA as a novel substrate/inhibitor pair to untangle the role of OATP and MRP2 activity in liver diseases." @default.
- W3031325065 created "2020-06-05" @default.
- W3031325065 creator A5004953156 @default.
- W3031325065 creator A5007445634 @default.
- W3031325065 creator A5010428627 @default.
- W3031325065 creator A5012340098 @default.
- W3031325065 creator A5019924722 @default.
- W3031325065 creator A5046856595 @default.
- W3031325065 creator A5054643240 @default.
- W3031325065 creator A5078826096 @default.
- W3031325065 creator A5083583275 @default.
- W3031325065 date "2020-05-27" @default.
- W3031325065 modified "2023-10-18" @default.
- W3031325065 title "Validation of Pharmacological Protocols for Targeted Inhibition of Canalicular MRP2 Activity in Hepatocytes Using [99mTc]mebrofenin Imaging in Rats" @default.
- W3031325065 cites W152943885 @default.
- W3031325065 cites W1675359132 @default.
- W3031325065 cites W1783939843 @default.
- W3031325065 cites W1879507592 @default.
- W3031325065 cites W1936741949 @default.
- W3031325065 cites W1966205026 @default.
- W3031325065 cites W1975500979 @default.
- W3031325065 cites W1978190051 @default.
- W3031325065 cites W1981204224 @default.
- W3031325065 cites W1997421176 @default.
- W3031325065 cites W1999689258 @default.
- W3031325065 cites W1999689787 @default.
- W3031325065 cites W2007736238 @default.
- W3031325065 cites W2012721995 @default.
- W3031325065 cites W2013854594 @default.
- W3031325065 cites W2034245991 @default.
- W3031325065 cites W2044459219 @default.
- W3031325065 cites W2046498746 @default.
- W3031325065 cites W2047527636 @default.
- W3031325065 cites W2052329451 @default.
- W3031325065 cites W2052655560 @default.
- W3031325065 cites W2052736173 @default.
- W3031325065 cites W2076488931 @default.
- W3031325065 cites W2079197876 @default.
- W3031325065 cites W2084769078 @default.
- W3031325065 cites W2097582326 @default.
- W3031325065 cites W2098118571 @default.
- W3031325065 cites W2101590862 @default.
- W3031325065 cites W2101656479 @default.
- W3031325065 cites W2102546020 @default.
- W3031325065 cites W2144948193 @default.
- W3031325065 cites W2168239564 @default.
- W3031325065 cites W2344748167 @default.
- W3031325065 cites W2410783394 @default.
- W3031325065 cites W2462454606 @default.
- W3031325065 cites W2475729613 @default.
- W3031325065 cites W2588651832 @default.
- W3031325065 cites W2593535068 @default.
- W3031325065 cites W2607470662 @default.
- W3031325065 cites W2608581123 @default.
- W3031325065 cites W2608831000 @default.
- W3031325065 cites W2792859300 @default.
- W3031325065 cites W2801270813 @default.
- W3031325065 cites W2804552830 @default.
- W3031325065 cites W2887042781 @default.
- W3031325065 cites W2887655204 @default.
- W3031325065 cites W2888658289 @default.
- W3031325065 cites W2910966200 @default.
- W3031325065 cites W2943186409 @default.
- W3031325065 cites W2999703571 @default.
- W3031325065 doi "https://doi.org/10.3390/pharmaceutics12060486" @default.
- W3031325065 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7355955" @default.
- W3031325065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32471244" @default.
- W3031325065 hasPublicationYear "2020" @default.
- W3031325065 type Work @default.
- W3031325065 sameAs 3031325065 @default.
- W3031325065 citedByCount "7" @default.
- W3031325065 countsByYear W30313250652021 @default.
- W3031325065 countsByYear W30313250652022 @default.
- W3031325065 countsByYear W30313250652023 @default.
- W3031325065 crossrefType "journal-article" @default.
- W3031325065 hasAuthorship W3031325065A5004953156 @default.
- W3031325065 hasAuthorship W3031325065A5007445634 @default.
- W3031325065 hasAuthorship W3031325065A5010428627 @default.
- W3031325065 hasAuthorship W3031325065A5012340098 @default.
- W3031325065 hasAuthorship W3031325065A5019924722 @default.
- W3031325065 hasAuthorship W3031325065A5046856595 @default.
- W3031325065 hasAuthorship W3031325065A5054643240 @default.
- W3031325065 hasAuthorship W3031325065A5078826096 @default.
- W3031325065 hasAuthorship W3031325065A5083583275 @default.
- W3031325065 hasBestOaLocation W30313250651 @default.
- W3031325065 hasConcept C10146269 @default.
- W3031325065 hasConcept C104317684 @default.
- W3031325065 hasConcept C112705442 @default.
- W3031325065 hasConcept C149011108 @default.
- W3031325065 hasConcept C150903083 @default.
- W3031325065 hasConcept C185592680 @default.
- W3031325065 hasConcept C207001950 @default.
- W3031325065 hasConcept C36201501 @default.
- W3031325065 hasConcept C44312359 @default.
- W3031325065 hasConcept C55493867 @default.
- W3031325065 hasConcept C71924100 @default.
- W3031325065 hasConcept C86803240 @default.
- W3031325065 hasConcept C98274493 @default.